Medicine
Sebastien Beauzile Is Pain-Free After Lyfgenia While a $3.1 Million Sickle Cell Therapy Still Barely Reaches Patients
Health News
March 14, 2025
Sebastien Beauzile Is Pain-Free After Lyfgenia While a $3.1 Million Sickle Cell Therapy Still Barely Reaches Patients
Sebastien Beauzile left sickle cell pain behind after Lyfgenia at Cohen Children's. Fewer than 40 patients have been infused, and the $3.1 million price still blocks the door.
IDO1 Cancer Drugs Restarted Astrocyte Glucose In Alzheimer’s Models While Kisunla’s Cleared Plaques Held And England Still Haggles
Health News
August 22, 2024
IDO1 Cancer Drugs Restarted Astrocyte Glucose In Alzheimer’s Models While Kisunla’s Cleared Plaques Held And England Still Haggles
Kisunla, approved in July 2024, can be stopped once amyloid plaques clear, and extension data showed most reductions holding for up to three years. IDO1 cancer inhibitors restored astrocyte glucose…